Actively Recruiting
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Led by National Taiwan University Hospital · Updated on 2025-05-22
315
Participants Needed
2
Research Sites
264 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
CONDITIONS
Official Title
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS)
- Patients undergoing breast-conserving surgery
- Age 20 years or older
- Karnofsky Performance Status (KPS) of 70% or higher
- Life expectancy of at least 5 years
- Adequate kidney and liver function
You will not qualify if you...
- Pregnant patients
- Patients requiring re-irradiation of the thoracic region
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Taiwan University Hospital
Taipei, Taiwan, Taiwan, 100
Not Yet Recruiting
2
National Taiwan University Hospital Yunlin Branch
Taipei, Taiwan, 632
Actively Recruiting
Research Team
Y
Yen-Ting Liu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here